Member Login
  1. Stocks
    2. /
  2. AstraZeneca PLC (LSE: AZN)
    3. /

LSE:AZN (AstraZeneca PLC)

About AZN

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.
Financial Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

AstraZeneca PLC (LSE: AZN) Latest News

Investing Articles

These FTSE 100 beauties are just too cheap to miss!

| Royston Wild

Royston Wild reveals two FTSE 100 (INDEXFTSE: UKX) firecrackers trading far, far too cheaply.

Read more »

Investing Articles

These dividend stocks won’t yield 4%+ forever

| Peter Stephens

Getting a 4%+ yield from these shares beats savings accounts, but may not be available for much longer.

Read more »

Investing Articles

These two FTSE 100 dividends stars still look cheap

| Rupert Hargreaves

These two FTSE 100 (INDEXFTSE: UKX) firms look like safe dividend champions but still appear to be undervalued.

Read more »

Investing Articles

Do these 3 low yielders offer high growth prospects?

| Harvey Jones

A sky-high yield isn't everything these days, is it? Harvey Jones investigates.

Read more »

Investing Articles

Is this a better healthcare buy than AstraZeneca plc after today’s update?

| Peter Stephens

Will this healthcare stock keep beating AstraZeneca plc (LON: AZN)?

Read more »

Investing Articles

Is Shield Therapeutics plc a better bet than AstraZeneca plc?

| Alan Oscroft

Does the small-cap potential of Shield Therapeutics plc (LON: STX) beat the blue chip reliability of AstraZeneca plc (LON: AZN)…

Read more »

Investing Articles

These two large caps look seriously undervalued

| Rupert Hargreaves

These two large caps could be the most undervalued in the FTSE 100.

Read more »

Investing Articles

Should you pile into this healthcare stock after today’s update?

| Peter Stephens

Is this healthcare stock a 'must-buy'?

Read more »

Investing Articles

Can you really trust these Footsie big yielders to pay out?

| Royston Wild

Royston Wild discusses the payout prospects of three FTSE 100 dividend stocks.

Read more »

Investing Articles

Is this the best healthcare stock money can buy after today’s update?

| Peter Stephens

Should you buy this stock or a sector peer following today's news?

Read more »

Investing Articles

Is now the right time to buy these Neil Woodford dividend stocks?

| Roland Head

In the light of recent gains, Roland Head takes a fresh look at three of fund manager Neil Woodford's biggest…

Read more »

Investing Articles

Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after today’s update?

| Edward Sheldon, CFA

Edward Sheldon looks at Hikma Pharmaceuticals plc's (LON: HIK) interim results statement and examines whether the long-term growth story is…

Read more »